Circulating CGRP as a diagnostic biomarker in female migraine patients: a single-center case-control study
Abstract
Migraine constitutes the predominant cause of disability-adjusted life years (DALYs), yet remains diagnostically challenging due to lack of biomarkers. Calcitonin gene-related peptide (CGRP) has been recognized as the pathophysiological cornerstone of migraine. Despite the therapeutic breakthrough of anti-CGRP therapies, their clinical efficacy remains limited. Given higher prevalence, frequency and severity of migraine in women, this study aims to investigate the diagnostic and therapeutic value of plasma CGRP in female migraine patients. This prospective observational study enrolled 184 female migraine patients and 85 healthy controls. CGRP concentrations were quantitatively analyzed using a magnetic particle chemiluminescent immunoassay (MP-CLIA) platform. High- and low-expression subgroups were stratified according to a predefined cutoff value of serum CGRP levels. Additionally, patients who received the CGRP receptor antagonist rimegepant during the acute phase of migraine were analyzed. Circulating CGRP concentrations were significantly higher in female migraine patients than those in healthy controls. Receiver operating characteristic (ROC) curve analysis determined that 40.00 pg/mL was the optimal cutoff value for subgroup stratification of CGRP levels. Using this threshold, migraine patients were classified into a high-CGRP subgroup (n = 112) and a low-CGRP subgroup (n = 72). A comparative analysis showed that the high-CGRP group had a higher monthly migraine attack…
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 184 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.